Patient and donor characteristics
| . | MSDs (N = 450) . | URDs (N = 2464) . | P . |
|---|---|---|---|
| Male (%) | 286 (63) | 1455 (59) | .08 |
| Median age, y (range) | 39 (3-59) | 36 (1-62) | .001 |
| Younger than 20 (%) | 12 (3) | 272 (11) | |
| 20 to 39 (%) | 205 (46) | 1195 (49) | |
| 40 and older (%) | 233 (52) | 997 (40) | |
| Disease stage at BMT | .001 | ||
| Chronic phase (%) | 369 (82) | 1654 (67) | .10 |
| Accelerated/remission after blast phase (%) | 60 (13) | 664 (27) | |
| Blast phase (%) | 20 (4) | 137 (6) | |
| Uncertain (%) | 1 (0.2) | 9 (0.4) | |
| Months from diagnosis to BMT, median (range) | 7 (1-118) | 17 (0-325) | .001 |
| 1 to 12 (%) | 320 (71) | 896 (36) | |
| 13 to 24 (%) | 84 (19) | 713 (29) | |
| 24 and more (%) | 46 (10) | 855 (35) | |
| Pre-BMT performance status* | .0001 | ||
| 90 to 100 (%) | 387 (86) | 2030 (83) | |
| Up to 80 (%) | 63 (14) | 421 (17) | |
| GVH disease prophylaxis | |||
| T-cell depletion (%) | 68 (15) | 487 (20) | .02 |
| Cyclosporine/tacrolimus (%) | 373 (83) | 1898 (77) | |
| Other (%) | 9 (2) | 79 (3) | |
| Pre-BMT conditioning | |||
| TBI + cyclophosphamide + other (%) | 287 (64) | 2053 (83) | .001 |
| Chemotherapy only (%) | 163 (36) | 411 (17) | |
| Median donor age, y (range) | 38 (1-71) | 37 (18-59) | .005 |
| Female donors (%) | 225 (50) | 1040 (42) | .002 |
| Interferon pre-BMT (%) | 104 (23) | 1355 (55) | < .001 |
| CMV | |||
| recipient − donor − (%) | 117 (26) | 855 (35) | .001 |
| recipient − donor + (%) | 67 (15) | 391 (16) | |
| recipient + donor ± (%) | 266 (59) | 1218 (49) |
| . | MSDs (N = 450) . | URDs (N = 2464) . | P . |
|---|---|---|---|
| Male (%) | 286 (63) | 1455 (59) | .08 |
| Median age, y (range) | 39 (3-59) | 36 (1-62) | .001 |
| Younger than 20 (%) | 12 (3) | 272 (11) | |
| 20 to 39 (%) | 205 (46) | 1195 (49) | |
| 40 and older (%) | 233 (52) | 997 (40) | |
| Disease stage at BMT | .001 | ||
| Chronic phase (%) | 369 (82) | 1654 (67) | .10 |
| Accelerated/remission after blast phase (%) | 60 (13) | 664 (27) | |
| Blast phase (%) | 20 (4) | 137 (6) | |
| Uncertain (%) | 1 (0.2) | 9 (0.4) | |
| Months from diagnosis to BMT, median (range) | 7 (1-118) | 17 (0-325) | .001 |
| 1 to 12 (%) | 320 (71) | 896 (36) | |
| 13 to 24 (%) | 84 (19) | 713 (29) | |
| 24 and more (%) | 46 (10) | 855 (35) | |
| Pre-BMT performance status* | .0001 | ||
| 90 to 100 (%) | 387 (86) | 2030 (83) | |
| Up to 80 (%) | 63 (14) | 421 (17) | |
| GVH disease prophylaxis | |||
| T-cell depletion (%) | 68 (15) | 487 (20) | .02 |
| Cyclosporine/tacrolimus (%) | 373 (83) | 1898 (77) | |
| Other (%) | 9 (2) | 79 (3) | |
| Pre-BMT conditioning | |||
| TBI + cyclophosphamide + other (%) | 287 (64) | 2053 (83) | .001 |
| Chemotherapy only (%) | 163 (36) | 411 (17) | |
| Median donor age, y (range) | 38 (1-71) | 37 (18-59) | .005 |
| Female donors (%) | 225 (50) | 1040 (42) | .002 |
| Interferon pre-BMT (%) | 104 (23) | 1355 (55) | < .001 |
| CMV | |||
| recipient − donor − (%) | 117 (26) | 855 (35) | .001 |
| recipient − donor + (%) | 67 (15) | 391 (16) | |
| recipient + donor ± (%) | 266 (59) | 1218 (49) |
Karnofsky performance status %.